Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survivalCancer.  125:921-932. 2019
2019 Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancerOncoImmunology.  8. 2019
2019 Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failureLaboratory Investigation.  99:371-386. 2019
2019 Molecular correlates of metastasis by systematic pan-cancer analysis across the cancer genome atlasCell Growth and Differentiation.  17:476-487. 2019
2019 The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtypePLoS ONE.  14. 2019
2019 Ferritin light chain confers protection against sepsis-induced inflammation and organ injuryFrontiers in Immunology.  10. 2019
2019 Integrative epigenetic and gene expression analysis of renal tumor progression to metastasisCell Growth and Differentiation.  17:84-96. 2019
2018 Wnt receptor Frizzled 8 is a target of ERG in prostate cancerProstate.  78:1311-1320. 2018
2018 A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer ProgressionNeoplasia : An International Journal for Oncology Research.  20:894-904. 2018
2018 Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic TargetsEuropean urology focus.  4:733-736. 2018
2018 miR-34a regulates expression of the stathmin-1 oncoprotein and prostate cancer progressionCell Growth and Differentiation.  16:1125-1137. 2018
2018 Erratum to: Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer: Purine Biosynthetic Gene in Prostate Cancer (The Prostate, (2017), 77, 1, (10-21), 10.1002/pros.23243)Prostate.  78:693-694. 2018
2018 214 High fat diet accelerates UVB-induced development of basal cell and squamous cell carcinoma in Ptch+/-/SKH-1 miceJournal of Investigative Dermatology.  138:S36-S36. 2018
2018 Histone methyltransferase ezh2: A therapeutic target for ovarian cancerMolecular Cancer Therapeutics.  17:591-602. 2018
2018 Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behaviorCollagen and related research.  65:104-118. 2018
2017 Prostate Cancer: An Update on Molecular Pathology with Clinical ImplicationsEuropean Urology Supplements.  16:253-271. 2017
2017 Prostate cancer imaging and biomarkers guiding safe selection of active surveillanceFrontiers in Oncology.  7. 2017
2017 UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival AnalysesNeoplasia : An International Journal for Oncology Research.  19:649-658. 2017
2017 Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate CancerCancer Cell.  31:532-548.e7. 2017
2017 Erratum: Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer (Cancer Cell (2017) 31(4) (532–548.e7)(S1535610817300600)(10.1016/j.ccell.2017.02.017))Cancer Cell.  31:844-847. 2017
2017 Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cellsScientific Reports.  7. 2017
2017 Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphomaLeukemia & Lymphoma.  58:179-184. 2017
2017 Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate CancerProstate.  77:10-21. 2017
2016 MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancerOncogene.  35:6330-6340. 2016
2016 Genomic and Epigenomic Alterations in CancerAmerican Journal of Pathology.  186:1724-1735. 2016
2016 Divergent clonal evolution of castration-resistant neuroendocrine prostate cancerNature Medicine.  22:298-305. 2016
2016 Erratum: TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer (Nature Communications (2014) 5 (4527) DOI: 10.1038/ncomms5527)Nature Communications.  7. 2016
2016 Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas.J Dig Dis Hepatol.  2016. 2016
2016 Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restrictionNature Immunology.  17:95-103. 2016
2015 Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinomaCell Cycle.  14:2798-2809. 2015
2015 Cancer: The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signalingScience Signaling.  8. 2015
2015 Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancerOncotarget.  6:23445-23461. 2015
2014 TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancerNature Communications.  5. 2014
2014 The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progressionOncotarget.  5:6654-6669. 2014
2013 Targeting the link between late pregnancy and breast cancereLife.  2013. 2013
2013 Prostate cancer genomics: Progress and promiseEuropean Urology.  64:577-578. 2013
2013 Erratum: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression (Nature (2009) 457 (910-914) DOI: 10.1038/nature07762)Nature.  499:504. 2013
2013 Erratum to Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer [Cancer Cell, 19 (2011) 664-678]Cancer Cell.  23:557. 2013
2013 Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in CancerMolecular Cell.  49:80-93. 2013
2012 The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells.Journal of Biological Chemistry.  287:43862-43875. 2012
2012 Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer modelsProstate.  72:1542-1549. 2012
2012 Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cellsBlood.  119:1274-1282. 2012
2012 Role of transcriptional corepressor CtBP1 in prostate cancer progressionNeoplasia : An International Journal for Oncology Research.  14:905-914. 2012
2011 The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinomaOncogene.  30:4339-4349. 2011
2011 Coordinated Regulation of Polycomb Group Complexes through microRNAs in CancerCancer Cell.  20:187-199. 2011
2011 TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancersCancer Research.  71:5387-5392. 2011
2011 Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortalityBlood.  117:6172-6183. 2011
2011 Characterization of KRAS rearrangements in metastatic prostate cancerCancer Discovery.  1:35-43. 2011
2011 Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate CancerCancer Cell.  19:664-678. 2011
2011 Therapeutic targeting of SPINK1-positive prostate cancerScience Translational Medicine.  3. 2011
2010 The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancerOncogene.  29:5370-5380. 2010
2010 Letter to the editorEuropean Urology.  58. 2010
2010 Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaNature Medicine.  16:793-798. 2010
2010 An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer ProgressionCancer Cell.  17:443-454. 2010
2010 Antibody-based detection of ERG rearrangement-positive prostate cancerNeoplasia : An International Journal for Oncology Research.  12:590-598. 2010
2010 Chlorpromazine induced cataract in a young patient with schizophrenia.Indian Journal of Psychological Medicine.  32:69-70. 2010
2009 Induced chromosomal proximity and gene fusions in prostate cancerScience.  326:1230. 2009
2009 An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancerNature Biotechnology.  27:1005-1011. 2009
2009 Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetasesPLoS ONE.  4. 2009
2009 AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistProceedings of the National Academy of Sciences.  106:10284-10289. 2009
2009 Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature.  457:910-914. 2009
2009 Tomlins et al. replyNature.  457. 2009
2009 RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer diseaseNeoplasia : An International Journal for Oncology Research.  11:956-963. 2009
2008 Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancerScience.  322:1695-1699. 2008
2008 Repression of E-cadherin by the polycomb group protein EZH2 in cancerOncogene.  27:7274-7284. 2008
2008 A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancerCancer Research.  68:7629-7637. 2008
2008 The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell.  13:519-528. 2008
2008 Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancerCancer Research.  68:73-80. 2008
2008 Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancerNeoplasia : An International Journal for Oncology Research.  10:1285-1294. 2008
2008 Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1American Journal of Pathology.  172:893-904. 2008
2008 Role of the TMPRSS2-ERG gene fusion in prostate cancerNeoplasia : An International Journal for Oncology Research.  10:177-188. 2008
2007 Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibitionProceedings of the National Academy of Sciences.  104:19488-19493. 2007
2007 A polycomb repression signature in metastatic prostate cancer predicts cancer outcomeCancer Research.  67:10657-10663. 2007
2007 Integrative Genomics Analysis Reveals Silencing of β-Adrenergic Signaling by Polycomb in Prostate CancerCancer Cell.  12:419-431. 2007
2007 Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancerNature.  448:595-599. 2007
2007 Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicityOncogene.  26:3431-3439. 2007
2007 Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivoClinical Cancer Research.  13:2512-2518. 2007
2007 Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinomaCancer Research.  67:3461-3467. 2007
2007 Molecular concepts analysis links tumors, pathways, mechanisms, and drugsNeoplasia : An International Journal for Oncology Research.  9:443-454. 2007
2007 Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profilesNeoplasia : An International Journal for Oncology Research.  9:166-180. 2007
2006 Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiationCancer Research.  66:11554-11559. 2006
2006 Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2′,5′-oligoadenylate synthetase from prostate cancer cellsNucleic Acids Research.  34:6684-6695. 2006
2006 Differential proteomic alterations between localised and metastatic prostate cancerBritish Journal of Cancer.  95:425-430. 2006
2006 A systems approach to model metastatic progressionCancer Research.  66:5537-5539. 2006
2006 Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibitionInternational Journal of Cancer.  118:1041-1050. 2006
2006 Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivoJournal of Experimental Medicine.  203:203-213. 2006
2006 ADAM15 disintegrin is associated with aggressive prostate and breast cancer diseaseNeoplasia : An International Journal for Oncology Research.  8:319-329. 2006
2006 Defining aggressive prostate cancer using a 12-gene modelNeoplasia : An International Journal for Oncology Research.  8:59-68. 2006
2005 Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysisCancer Research.  65:11259-11264. 2005
2005 Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progressionCancer Cell.  8:393-406. 2005
2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancerScience.  310:644-648. 2005
2005 Autoantibody signatures in prostate cancerNew England Journal of Medicine.  353:1224-1235. 2005
2005 Probabilistic model of the human protein-protein interaction networkNature Biotechnology.  23:951-959. 2005
2005 The unfolded protein response modulates toxicity of the expanded glutamine androgen receptorJournal of Biological Chemistry.  280:21264-21271. 2005
2005 α-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysisCancer Epidemiology, Biomarkers and Prevention.  14:1418-1423. 2005
2005 Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)Cancer Research.  65:3328-3335. 2005
2005 The polycomb group protein EZH2 impairs DNA repair in breast epithelial cellsNeoplasia : An International Journal for Oncology Research.  7:1011-1019. 2005
2004 Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy programCancer Research.  64:9209-9216. 2004
2004 JAGGED1 expression is associated with prostate cancer metastasis and recurrenceCancer Research.  64:6854-6857. 2004
2004 Natural antibodies sustain differentiation and maturation of human dendritic cellsProceedings of the National Academy of Sciences.  101:14210-14215. 2004
2004 Overexpression, amplification, and androgen regulation of TPD52 in prostate cancerCancer Research.  64:3814-3822. 2004
2004 Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cellsInternational Immunology.  16:517-524. 2004
2004 The Role of Metastasis-Associated Protein 1 in Prostate Cancer ProgressionCancer Research.  64:825-829. 2004
2004 C5a-Induced Gene Expression in Human Umbilical Vein Endothelial CellsAmerican Journal of Pathology.  164:849-859. 2004
2003 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProceedings of the National Academy of Sciences.  100:11606-11611. 2003
2002 Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimensAmerican Journal of Pathology.  161:1743-1748. 2002
2002 The polycomb group protein EZH2 is involved in progression of prostate cancerNature.  419:624-629. 2002
2002 Autoantibodies to heat shock protein 90 in the human natural antibody repertoireInternational Immunology.  14:453-461. 2002
2002 α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancerJournal of the American Medical Association.  287:1662-1670. 2002
2002 Molecular cross-talk between the TRAIL and interferon signaling pathwaysJournal of Biological Chemistry.  277:575-585. 2002
2002 α-Methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiationAmerican Journal of Pathology.  161:841-848. 2002
2001 Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteinsCancer Research.  61:7585-7593. 2001
2001 Delineation of prognostic biomarkers in prostate cancerNature.  412:822-826. 2001
2001 Variable Sensitivity of Lymphoblastoid Cells to Apoptosis Induced by Viscum album Qu FrF, a Therapeutic Preparation of Mistletoe LectinChemotherapy.  47:366-376. 2001
2000 Natural Antibodies to Factor VIIISeminars in Thrombosis and Hemostasis.  Volume 26:157-166. 2000
1999 Catalytic activity of antibodies against factor VIII in patients with hemophilia ANature Medicine.  5:1044-1047. 1999
1998 Refolding of native and recombinant chicken riboflavin carrier (or binding) protein : evidence for the formation of non-native intermediates during the generation of active proteinEuropean Journal of Biochemistry.  258:411-418. 1998
1998 Identification and characterization of receptors for riboflavin carrier protein in the chicken oocyteBBA - Proteins and Proteomics.  1382:230-242. 1998
1996 Hyperexpression of Chicken Riboflavin Carrier Protein: Antibodies to the Recombinant Protein Curtail Pregnancy in RodentsProtein Expression and Purification.  7:147-154. 1996

Research Overview

  • Cancer Genomics, Epigenetics, Proteomics, Signal Transduction, Bioinformatics, Cancer Biology and Target Discovery. Therapeutic Targeting.
  • Education And Training

  • Hôpital Broussais, INSERM Unit, Postdoctoral Research 2000
  • Doctor of Philosophy in Biochemistry, Indian Institute of Science 1997
  • Master of Science in Biochemistry, Manipal University 1991
  • Bachelor of Science or Mathematics in Chemistry, Mangalore University 1989
  • Full Name

  • Sooryanarayana Varambally